-
Product Insights
Nanao Shiga Wind Power Generation Project
Nanao Shiga Wind Power Generation Project is an Onshore Wind project located in Ishikawa, Japan. The project is owned by Mitsubishi Corp Energy Solutions Co Ltd and is developed by AR Wind Power Co Ltd; Iberdrola Renewables Japan KK; Nanao Shiga Wind Farm GK. The project is at the permitting stage. Empower your strategies with our Nanao Shiga Wind Power Generation Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon...
-
Product Insights
NewLikelihood of Approval Analysis for Hemolytic Uremic Syndrome
Overview How likely is it that the drugs in Hemolytic Uremic Syndrome will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hemolytic Uremic Syndrome Overview Hemolytic uremic syndrome (HUS) is a rare...
-
Company Insights
Innovation and Patenting activity of The Shiga Bank Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of The Shiga Bank Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Seasonal Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Seasonal Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-8421 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-8421 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-8421 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-8421 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-8421 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-8421 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Fusion...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-8421 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-8421 in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-8421 in Malignant Mesothelioma Drug Details: Fusion proteins are under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-8421 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-8421 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-8421 in Metastatic Renal Cell Carcinoma Drug Details: Fusion...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-8421 in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-8421 in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-8421 in Metastatic Transitional (Urothelial) Tract Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-8421 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-8421 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-8421 in Cervical Cancer Drug Details: Fusion proteins are under development...